Aranidipine

Aranidipine is an antagonist of voltage-gated calcium channel Ca_v3.2.¹ It inhibits inward currents in Xenopus oocytes expressing human Ca_v3.2 channels when used at a concentration of 10 µM. Aranidipine (10 mg/kg) decreases mean blood pressure and increases heart rate in spontaneously hypertensive rats (SHRs).² It increases aortic and coronary blood flow and decreases blood pressure, but not heart rate, in normotensive dogs when administered at a dose of 0.3 mg/kg. Aranidipine (10 µg/kg) decreases blood pressure, as well as increases coronary blood flow velocity and heart contractile force, in dogs.³ It inhibits diet-induced increases in serum levels of total cholesterol, phospholipids, and triglycerides, as well as reduces aortic plaque area, in rabbits fed a high-cholesterol diet when administered at doses of 3 or 10 mg/kg. Formulations containing aranidipine have been used in the treatment of hypertension.

WARNING This product is not for human or veterinary use.

1. Furukawa, T., Nukada, T., Namiki, Y., et al. Five different profiles of dihydropyridines in blocking T-type Ca²⁺ channel subtypes (Ca_v3.1 (α1G), Ca_v3.2 (α1H), and Ca_v3.3 (α1I)) expressed in Xenopus oocytes. Eur. J. Pharmacol. 613(1-3), 100-107 (2009).

2. Kanda, A., Haruno, A., Miyake, H., et al. Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs. J. Cardiovasc. Pharmacol. 20(5), 723-730 (1992).

3. Kanda, A., Haruno, A., Miyoshi, K., et al. Cardiovascular profile of MPC-1304, a novel dihydropyridine calcium antagonist: Comparison with other calcium antagonists. J. Cardiovasc. Pharmacol. 22(1), 167-175 (1993).